...
首页> 外文期刊>Future medicinal chemistry >Drug discovery for the treatment of leishmaniasis, African sleeping sickness and Chagas disease
【24h】

Drug discovery for the treatment of leishmaniasis, African sleeping sickness and Chagas disease

机译:发现用于治疗利什曼病,非洲昏睡病和恰加斯病的药物

获取原文
获取原文并翻译 | 示例
           

摘要

The trypanosomatid protozoa Leishmania, Trypanosoma brucei and Trypanosoma cruzi are the caustive agents of the human diseases respectively, leishmaniasis, African sleeping sickness and Chagas disease. Among the 17 'neglected tropical diseases' highlighted by WHO, progress towards the treatment of these diseases has improved in recent decades, as a result of increased awareness, the emergence of public-private research partnerships and advances in drug-discovery technologies and techniques. Despite this, the current therapies for these diseases have serious shortcomings and, as such, the need to develop novel drugs, improve diagnosis and control the spread of disease is of paramount importance. Future Medicinal Chemistry invited leading experts in the field to share their thoughts and opinions on the changing face of drug discovery in the pursuit of treatments for trypanosomatid-based diseases.
机译:锥虫原虫利什曼原虫,布鲁氏锥虫和克氏锥虫分别是人类疾病,利什曼病,非洲昏睡病和南美锥虫病的致病因子。在世卫组织强调的17种“被忽视的热带病”中,由于人们认识的提高,公私合作伙伴关系的出现以及药物发现技术的进步,在这些疾病的治疗方面取得了进步。尽管如此,目前用于这些疾病的疗法仍然存在严重的缺陷,因此,开发新药,改善诊断和控制疾病传播的需求至关重要。未来药物化学邀请了该领域的领先专家分享他们在寻求基于锥虫病的疾病治疗中不断变化的药物发现方面的想法和观点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号